WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Results 1-10 of 203 for Criteria: Office(s):all Language:ES Stemming: true maximize
Página anterior 1 2 3 4 5 6 7 8 9 10 Página siguiente
Page: / 21  Go >
RSS iconmap icon 

Analysis
Analysis

List Length
Machine translation
TitleCtrPubDate
Int.ClassAppl.NoApplicantInventor
1. WO/2015/104008 CONJUGATE COMPRISING ERYTHROPOIETIN AND A BRANCHED POLYMER STRUCTUREWO16.07.2015
A61K 38/18
PCT/CU2015/000001CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAPÁEZ MEIRELES, Rolando
The invention relates to: a conjugate comprising erythropoietin (EPO) and an asymmetric branched polymer structure having two monomethoxy-poly(ethylene glycol) (mPEG) branches, wherein the molecular mass of one of said mPEG branches is between 10 kDa and 14 kDa, and the molecular mass of the other mPEG branch is between 17 kDa and 23 kDa; and pharmaceutical compositions containing said conjugate. The invention also relates to a method for producing PEGylated EPO, characterised in that said protein is conjugated to an asymmetric branched polymer structure, having two mPEG branches with the above-mentioned molecular masses.

2. WO/2015/014327 DIVALENT VACCINE COMPOSITIONS AND THE USE THEREOF FOR TREATING TUMOURSWO05.02.2015
A61K 39/00
PCT/CU2014/000004CENTRO DE INMUNOLOGÍA MOLECULARSÁNCHEZ RAMÍREZ, Belinda
A description is given of vaccine compositions that combine, in equal proportions, the extracellular domains of Her1 and Her2 growth factor receptors or fragments thereof and, in addition, proteoliposomes of very small size deriving from outer membrane proteins of Neisseria meningitidis and GM3 ganglioside (GM3/VSSP), which are intended for subcutaneous administration. The compositions described allow antibodies to be induced for treating malignant tumours and offer advantages owing to the fact that they successfully eliminate the entire mass of the tumour and prevent return of the tumour from the appearance of resistant variants.

3. WO/2014/206379 FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIESWO31.12.2014
A61B 5/055
PCT/CU2014/000003CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIACABAL MIRABAL, Carlos Alberto
The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.

4. WO/2014/190953 PROSTHETIC SYSTEM FOR REPLACING THE OSSICLES OF THE MIDDLE EARWO04.12.2014
PCT/CU2014/000002CENTRO DE NEUROCIENCIAS DE CUBA (NEURONIC)GONZALEZ SANTOS, Ramòn
The invention concerns a prosthetic system for replacing the ossicles of the middle ear, designed both for partial (anvil or stirrup) and total (both components) replacement of the chain of ossicles of the middle ear, in order to restore hearing in patients suffering from a loss of hearing for this reason. The system is produced preferably from biocompatible photopolymers of which the bioactivity is increased by the addition of micro- and nanoparticles of calcium carbonates, phosphates, hydroxide, titanium oxide, hydroxyapatite and carbonate apatite, or a mixture thereof. It is thus possible to monitor the patients post-operatively, using any of the imaging technologies since the density of the material from which the prosthetic system is produced is very similar to that of bone. In all cases, complete stability of the implant can be attained by securing it by way of a fastener system, complemented if necessary with a cementing substance which is biocompatible with the bone.

5. WO/2014/131375 PHOTOPOLYMERISABLE COMPOSITE BIOMATERIALS FOR 3D PRINTING OF IMPLANTSWO04.09.2014
PCT/CU2014/000001CENTRO DE NEUROCIENCIAS DE CUBA (NEURONIC)GONZALEZ SANTOS, Ramón
The invention relates to photopolymerisable composite biomaterials for 3D printing of implants, formed by biocompatible mixtures of polymers derived from urethane dimethacrylate (UDMA), tetrahydrofurfuryl methacrylate (THFMA), methyl methacrylate (MMA), methyl polymethylmethacrylate (PMMA), 2-hydroxyethyl methacrylate (HEMA), neopentylglycol diacrylate propoxylate(NPGDP), vinyl acetate (VAc) and polyvinyl acetate (PVAc) combined with photoinitiators and mixtures of nano and microparticles of inorganic composites of hydroxycarbonate phosphates of calcium and titanium oxide. The mixtures are used as a printing material in the 3D printers which are operated by means of photopolymerisation using ultraviolet-visible light (stereolithography) and allow the exact reproduction or printing of virtual solid images of parts of tissues and organs made by means of computer-assisted design (CAD) or generated or reproduced from medical images such as CAT, NMR and others. The products obtained when polymerised with ultraviolet-visible radiation have suitable mechanical and biocompatibility properties for producing implantable medical devices by means of stereolithography 3D printing.

6. WO/2014/131374 CHEMICAL CHAPERONINS AS NOVEL MOLECULAR MODULATORS OF BETA PROTEIN AGGREGATION PRESENT IN CONFORMATIONAL DISEASESWO04.09.2014
A61K 31/167
PCT/CU2013/000009CENTRO DE NEUROCIENCIAS DE CUBA (NEURONIC)SABLON CARRAZANA, Marquiza
The invention relates to chemistry and biochemistry applied to the field of medicine, and particularly to a novel method for the prevention and therapeutic treatment of conformational diseases (CD), especially diseases of an amyloid origin, by means of the administration of an effective quantity of at least one compound, the salts, prodrugs or solvates thereof, considered in this invention as chemical chaperonins, of formula I wherein: R1 is -alkylenyl-C(O)NH-alkylenyl-R3, -alkylenyl-C(O)O-R4; R3 is -COOH, -OH, -SH, -NH2, -NH-alkyl, -NH-alkyl dithiocarbamate, -N/-(alkyl)-dithiocarbamate of salts of alkaline earth metals or salts of the previously related groups, that are pharmaceutically acceptable, for the treatment of amyloidogenic diseases; R4 is a succinimide group; and R2 is -H, -alkyl.

7. WO/2014/101903 DENGUE VIRUS VACCINE COMPOSITIONWO03.07.2014
A61K 39/12
PCT/CU2013/000008CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAHERMIDA CRUZ, Lisset
Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.

8. WO/2014/071894 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOFWO15.05.2014
A61K 38/18
PCT/CU2013/000007CENTRO DE INMUNOLOGIA MOLECULARCORRIA OSORIO, Ángel de Jesús
The invention relates to branches of biotechnology and, in particular, to mutated polypeptides of the TGFß molecule, the primary sequence of which is highly homologous with the sequence of human TGFß. These muteins lose their ability to interact with ALK5 but retain their ability to interact with the rest of the receptors that form part of the receptor complex (TßRII and TßRIII). In addition, they can antagonise the signalling of all of the natural variants of the TGFß ligands, dependent on the recruitment of ALK5 in the receptor complex, and they have an immunomodulatory effect. The invention also relates to pharmaceutical compositions comprising, as active principle, the disclosed polypeptides or fusion proteins and to the therapeutic use of the disclosed polypeptides, fusion proteins and pharmaceutical compositions owing to their immunomodulatory effect on diseases such as cancer, diseases associated with fibrosis and chronic infectious diseases.

9. WO/2014/067498 CHIMERIC VACCINE ANTIGENS AGAINST HEPATITIS C VIRUSWO08.05.2014
A61K 39/12
PCT/CU2013/000006CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIADUEÑAS CARRERA, Santiago
The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV), comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially-formed specific epitopes for auxiliary T cells. The chimeric antigens, and the resulting vaccine compositions, are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.

10. WO/2014/044230 METHOD FOR OBTAINING 1-KESTOSEWO27.03.2014
C12P 19/18
PCT/CU2013/000005CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAPÉREZ CRUZ, Enrique, Rosendo
The invention relates to a method for obtaining 1-kestose on an industrial scale, using a recombinant fructosyltransferase (FTF) isolated from Festuca arundinacea, constitutively expressed in a non saccharolytic yeast host. According to the invention, the recombinant FTF of the sucrose:sucrose 1-fructosyltransferase (1-SSTrec) type is produced in a constitutive and stable manner and in high yields, both in the supernatant and in the cell sediment of the culture of a strain of Pichia pastoris. The invention also relates to a method for obtaining 1-SST on an industrial scale. The resulting recombinant enzyme is used for the mass enzymatic production of fructooligosaccharides (FOS), specifically 1-kestose, from sucrose. The method of the invention allows FOS conversion percentages greater than 55%, with 1-kestose being represented in more than 90%.


Results 1-10 of 203 for Criteria: Office(s):all Language:ES Stemming: true
Página anterior 1 2 3 4 5 6 7 8 9 10 Página siguiente